Clinical Trials Sponsored by Robert Morris

Total 2168 results

University of Pittsburgh
Robert Morris University

Completed

Perianal Maceration in Pediatric Ostomy Closure Patients

Postoperative Complications | Ileostomy - Stoma | Perianal Dermatitis | Diaper Dermatitis | Colostomy Site

United States
Robert Ferris
Amgen

Completed

Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer

Head and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditions

United States
Robert Morris
National Cancer Institute (NCI)

Completed

Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer

Ovarian Cancer | Peritoneal Cavity Cancer

United States
Robert Ferris
Bristol-Myers Squibb

Completed

ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of the Head and Neck

United States
Robert Ferris
Immune Cell Therapy Inc.

Withdrawn

Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Robert Scott Harris, M.D.
Gilead Sciences

Withdrawn

FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan

Pulmonary Arterial Hypertension

United States
Robert Ferris
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Head and Neck Cancer

Head and Neck Cancer

United States
Philip Morris Products S.A.

Terminated

Cross-Sectional Survey on the Use of Tobacco Products - Germany

Tobacco Use

Switzerland
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetics of THS Single Use of a Regular or a Menthol Stick Compared to CIG

Smoking, Tobacco

United Kingdom
Philip Morris Products S.A.

Completed

Reduced Exposure Study Using the CHTP 1.2 With 5 Days in a Confinement Setting Followed by 85 Days in an Ambulatory Setting.

Smoking

Poland
Philip Morris Products S.A.

Completed

Effect of Switching From Cigarette Smoking to IQOS on Exercise Capacity

Smoking | Exercise Capacity

Germany
Philip Morris Products S.A.

Completed

Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting

Smoking

United States
Philip Morris Products S.A.

Completed

Reduced Exposure Study in Smokers Using the Tobacco Heating System 2.2 (THS 2.2) for 5 Days in a Confinement Setting

Smoking

Japan
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P

Pharmacokinetics

Switzerland
Philip Morris Products S.A.

Completed

Study to Investigate the Nicotine Pharmacokinetic Profiles and Pharmacodynamic Effects of P4M3 Variants

Vaping | Nicotine Absorption

United States
Philip Morris Products S.A.

Completed

Exploratory THS 2.1 Biomarkers of Exposure Study (ZRHX-EX-01)

Smoking

Poland
Philip Morris Products S.A.

Completed

Exploratory THS 2.1 Nicotine Pharmacokinetics and Safety Study

Smoking

United Kingdom
Philip Morris Products S.A.

Completed

Smoking Research Study

Smoking | Non-smoking

United Kingdom
Philip Morris Products S.A.

Recruiting

Effect of Switching From Cigarette Smoking to THS on Disease Progression in Mild to Moderate COPD Subjects With Chronic Bronchitis Symptoms.

Smoking | Tobacco Use | COPD

United States, Bulgaria, Czechia, Germany, Japan, Romania, Slovakia, United Kingdom
Philip Morris Products S.A.

Completed

Reduced HPHC Exposure in Cigarette Smokers Switching to P4M3 Gen. 2.0 Compared to Continuing Smoking, or Smoking Abstinence

Nicotine | Nicotine Vaping | Vaping

United Kingdom
Philip Morris Products S.A.

Terminated

Cross-Sectional Survey on the Use of Tobacco Products - Italy

Tobacco Use

Switzerland
Philip Morris Products S.A.

Active, not recruiting

Pharmacokinetics and Comparative Bioavailability of Nicotine From Two Variants of NP2, NP2-4mg and NP2-6mg, Compared to Nicotine Lozenge 4mg (Loz-4mg) and Nicotine Gum 4mg (Gum-4mg)

Tobacco Use

Canada
Philip Morris Products S.A.

Active, not recruiting

Reduction of Exposure, Inflammation, and Oxidative Stress Following at Least 2 Years of Switching to THS Use Compared to Cigarette Smoking

Smoking | Inflammation | Oxidative Stress | Smoking Abstinence

Japan, Germany, Czechia, Greece
Philip Morris Products S.A.

Completed

Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking.

Smoking | Abdominal Aortic Aneurysm | IQOS Use

Japan
Philip Morris Products S.A.

Completed

A Smoking Cessation Study to Understand the Biological and Functional Changes After One Year of Smoking Cessation (RIBESC)

Cigarette Smoking

United States, Poland, Germany, Japan, United Kingdom
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetics and Subjective Effects of Nicotine Pouch 1.0 Compared to Velo® Ice Cool and Zyn® Cool Mint Mini Dry in Healthy Smokers

Smoking | Nicotine

United Kingdom
Philip Morris Products S.A.

Completed

Product Use and Adaptation, Safety and Tolerability of P3P in Adult Healthy Smokers Switching to it

Pharmacokinetics

Russian Federation
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetic Profile of the CHTP 1.1 M

Smoking

Japan
Philip Morris Products S.A.

Completed

Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting

Smoking

Japan
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol).

Smoking

Japan
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)

Smoking

United States
Philip Morris Products S.A.

Completed

Reduced Exposure Study in Smokers Using THS 2.2 With 5 Days in a Confinement Setting.

Smoking

Poland
Philip Morris Products S.A.

Completed

European Exposure Study

Smoking

United Kingdom
Philip Morris Products S.A.

Completed

User Acceptability of a Nicotine Lactate Delivery System (P3L)

Smoking

United States
Philip Morris Products S.A.

Unknown

Japanese Post-Market Cohort Study

Smoking | Tobacco Product

Japan
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)

Smoking

Japan
Philip Morris Products S.A.

Terminated

Cross-Sectional Survey on the Use of Tobacco Products - London (UK)

Tobacco Use

Switzerland
Philip Morris Products S.A.

Completed

Reduced Exposure to HPHC in Smokers Switching From Cigarettes to Different Versions of THS

Smoking | Tobacco Use | Tobacco Smoking

United Kingdom
Philip Morris Products S.A.

Withdrawn

Effect of Switching From Cigarette Smoking to THS on Systemic Endothelial Function in Subjects With Established Atherosclerotic Disease

Cardiovascular Diseases | Coronary Artery Disease | Smoking | Peripheral Arterial Disease | Tobacco Use
Philip Morris Products S.A.

Completed

Reduced Exposure Study Using CHTP 1.0 During 5 Days in Confinement.

Smoking

Poland
Philip Morris Products S.A.

Completed

Effect of Switching From Cigarette Smoking to the Use of IQOS on Periodontitis Treatment Outcome

Periodontal Diseases | Gingival Diseases | Chronic Periodontitis | Smoking, Cigarette | Periodontal Pocket | Tooth Mobility

Japan
Philip Morris Products S.A.

Completed

Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks

Smoking

United States
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes

Nicotine | Nicotine Vaping | Vaping

United States
Philip Morris Products S.A.

Completed

A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2

Smoking

United States
Philip Morris Products S.A.

Completed

Prefatory Study to Explore Changes in Nasal Mucociliary Clearance and to Standardize Nasal Scraping Procedure

Smokers | Never Smokers

United States
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)

Smoking

United Kingdom
Philip Morris Products S.A.

Completed

Nicotine Pharmacokinetic and Pharmacodynamics Profile, Safety and Tolerability of P3L

Smoking

New Zealand
Philip Morris Products S.A.

Completed

Determination of Biomarkers of Exposure and Biomarkers of Potential Harm in Asian Adult Cigarette Smokers

Smoking | Healthy

Japan
Philip Morris Products S.A.

Completed

Investigate the Exposure to Selected Smoke Constituents in Smokers Switching to Distillation Based Smoking Article

Smoking

Poland
Philip Morris Products S.A.

Completed

Real-Life Passive Exposure Assessment of IQOS

Environmental Exposure

Japan

3

Subscribe